Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Halometasone→

Halometasone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50629-82-8
Molecular formula
C22H27ClF2O5
Molecular weight
444.9 g/mol
Drug class
Topical glucocorticoid corticosteroid
Mechanism of action
Activates intracellular glucocorticoid receptors in skin cells, regulating transcription of inflammatory mediators and suppressing local immune and inflammatory responses. This reduces erythema, oedema and pruritus in corticosteroid-responsive dermatoses.
Indications / reported uses
  • Topical treatment of inflammatory and pruritic corticosteroid-responsive dermatoses, including eczema and dermatitis, according to the product label and local authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=halometasone · https://www.ncbi.nlm.nih.gov/mesh/?term=halometasone · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Topical glucocorticoid corticosteroid

Mechanism of action

Activates intracellular glucocorticoid receptors in skin cells, regulating transcription of inflammatory mediators and suppressing local immune and inflammatory responses. This reduces erythema, oedema and pruritus in corticosteroid-responsive dermatoses.

General use cases

  • Topical treatment of inflammatory and pruritic corticosteroid-responsive dermatoses, including eczema and dermatitis, according to the product label and local authorisation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Halometasone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Halometasone Permitted Daily Exposure (PDE) report (the Halometasone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Halometasone Occupational Exposure Limit (OEL) report (the Halometasone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.